Open AccessPropranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury
Author(s) -
Kota Daniel J.,
Prabhakara Karthik S.,
van Brummen Alexandra J.,
Bedi Supinder,
Xue Hasen,
DiCarlo Bryan,
Cox Charles S.,
Olson Scott D.
Publication year - 2016
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2015-0065
Subject(s) - traumatic brain injury , medicine , microglia , neuroprotection , propranolol , mesenchymal stem cell , neurogenesis , neuroinflammation , pharmacology , inflammation , bioinformatics , neuroscience , pathology , psychology , biology , psychiatry
In this study, an animal model of moderate‐severe traumatic brain injury (TBI) was treated with an acute dose of propranolol followed by a delayed dose of human mesenchymal stem cells (MSCs), resulting in improved short‐ and long‐term measurements. These results reinforce the inevitable clinical trial of MSCs to treat TBI by demonstrating, among other benefits, a notable decrease in chronic neuroinflammation and demonstrating that MSCs and propranolol are compatible treatments that improve overall outcome.